MedPath

Comparing the effects of bevacizumab and aflibercept in the treatment and outcome of patients with retinopathy of prematurity (ROP)

Not Applicable
Recruiting
Conditions
H35.1
Retinopathy of prematurity.
Retinopathy of prematurity
Registration Number
IRCT20240611062093N1
Lead Sponsor
Zahedan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Completion of patient files
Patients who need treatment
Patients needing treatment with anti-VEGF drugs

Exclusion Criteria

Patients with underlying disease, including congenital glaucoma, congenital cataract
Patients with vitreous hemorrhages

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath